Safety, Tolerability, and Efficacy of AT101 in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

Exclusion Criteria

• •Those who have previously had a history of treating homologic autologous hemoblastitis (allogeneic HSCT)
• •At101/adcidmilisers, anticancer chemotherapy/adcidms for lymphodeletion or those who are hypersensitive to tocilizumab
• •Those who cannot take autologous blood
• •Those who have received chemotherapy or radiotherapy, excluding lymphodeletion, within two weeks prior to IP administration
• •Persons who have not been recovered (CTCAE grade ≤1 or baseline) due to previous treatment
• •Those who have identified a condition that, at the test's discretion, may affect safety and validation during the trial period.
• •Those who have identified the following forces at the time of screening:
• •1. Those who have been clinically aware of heart disease within 6 months prior to screening
• •2. Those identified as thromboembolic disease, pulmonary embolism or bleeding bleeding diatheses within 6 months prior to screening
• •3. Those who have identified a history of malignant tumors other than B-cell non-Hodgkin's lymphoma within five years prior to screening
• •4. Those who have undergone major surgery within 4 weeks prior to screening
• •5. Those who have undergone non-critical surgery within two weeks prior to screening
• •Childbearing women or men who do not have the will to use effective contraception for a longer period of time, either 12 months after clinical trial period and AT101 administration or when AT101 in the body is not identified
• •Those who have been administered or applied to other IP/ID within 4 weeks of screening
• •Those who are addicted to alcohol and/or medication
• •Those who are unfit or unable to participate in this trial when judged by PI